Bank of New Hampshire’s Harmony Biosciences HRMY Stock Holding History

Bank of New Hampshire’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.94K	Buy	+218	New	+$6.88K	﹤0.01%	473

Other funds holding HRMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return

Bank of New Hampshire's HRMY Position: Q2 2026 in Review

Bank of New Hampshire opened a new position in Harmony Biosciences (HRMY) in Q2 2026: 218 shares worth $7.94K. The stake represents ﹤0.01% of the portfolio and ranks #473 among its holdings.

120 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

Bank of New Hampshire held 218 shares of Harmony Biosciences worth $7.94K as of Q2 2026.
Harmony Biosciences was a new Bank of New Hampshire position in Q2 2026.
Harmony Biosciences made up ﹤0.01% of Bank of New Hampshire's portfolio in Q2 2026, its #473 holding.
120 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Bank of New Hampshire's 13F filing for Q2 2026, filed 14 Jul 2026.